• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Damien Conover

Damien Conover

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  5. Research
  1. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover .

  2. Market Undervalues Merck’s Pipeline

    New products will secure the drug firm’s wide moat and help increase the firm’s valuation over time, writes Morningstar’s Damien Conover .

  3. Prescribe to Pharma for Emerging-Markets Growth

    Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover .

  4. J&J Faces Headwinds in 2015

    The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .

  5. Johnson & Johnson's Pharma Group Leading the Way

    The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .

  6. Pfizer-Astra Deal Will Get Done

    Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover .

  7. J&J's Strong 2Q Led by Pharmaceuticals

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .

  8. Ultimate Stock-Pickers’ Top 10 High-Conviction and New-Money Purchases

    Top managers were finding new places to put money to work and adding to existing high-conviction ideas in the first quarter.

  9. Friday Five: Banks Start Earnings Season Without a Bang

    Plus, strong results push Netflix shares further out of reach this week, while Google stock gets more interesting as European regulators make a move.

  10. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.